RxDoctor Payments Data

Taylor Brueseke, MD

Urogynecology and Reconstructive Pelvic Surgery · Orange, CANPI 1821304882

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,153 of the $3,243 with a category attached, or 66.4%. 11 manufacturers reported payments, led by Intuitive Surgical at 32.2% of the total. Reporting peaked in 2023 at $1,126 and has fallen 66.3% since, to $380 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in CA, where the typical reported total is $4,058.

$3,243in general payments, 2019–2025

Across 75 payments — averaging $43.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Medtronic$846
  • Axonics, Inc.$608
  • Bluewind Medical$238
  • AbbVie$139
  • Boston Scientific$136
  • plus $231 from 5 others
$51,061in research payments, 2019–2025

Across 22 payments — averaging $2320.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bluewind Medical$51K

What the payments were for

  • Travel & lodging$95629%
  • Food & beverage$2,15366%
  • Education$1344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,243 in reported general payments places this provider in the 40th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$80,072
Medicare patients
215
Services billed
2,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron82$50,534
GemtesaVibegron46$36,201
PremarinEstrogens, Conjugated45$19,467
EstringEstradiol14$7,475
Trospium Chloride ErTrospium Chloride26$3,874
Estradiol61$3,572
Methenamine Hippurate17$1,160
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$932
Trospium Chloride19$791
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$75

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →